The American Society of Clinical Oncology halted an ongoing study investigating a possible link between selenium and lung cancer due to lack of evidence connecting the two. The study results, presented at the American Society of Clinical Oncology 2010 Annual Meeting, showed that supplementing 200 mcg/d of selenium was as ineffective as placebo for reducing lung cancer recurrence or second primary malignancy.
Daniel Karp, M.D., from The University of Texas MD Anderson Cancer Center, stated: ‘Our results demonstrate that selenium is not an effective chemoprevention agent in an unselected group of lung cancer patients, and it’s not something we can recommend to our patients to prevent a second cancer from developing or recurring.’
